A panelist discusses how the potential of neurokinin-targeted therapies to provide targeted symptom relief with fewer side ...

A panelist discusses how neurokinin-targeted therapies can be strategically combined with existing treatments to address multiple vasomotor symptoms (VMS) while highlighting their positive impact on ...

It belongs to a class of drugs called neurokinin-1 (NK1) receptor antagonists. As a potent antiemetic, the medication works by blocking the neurokinin receptors in the brain and gut, which are ...